About the Speaker
Dr. Gerardo Turcatti, directs the academic technological platform, Biomolecular Screening Facility (BSF) at the EPFL (Swiss Federal Institute of Technology) he created in 2006. Previously he co-founded and acted as CTO of Manteia S.A., a Swiss-based company that developed revolutionary high throughput DNA sequencing technologies he transferred to Solexa and Lynx in 2004 (currently commercialized by Illumina Inc.) Prior to this experience, Dr Turcatti had a long multidisciplinary career in R&D divisions of Biotechnology and Pharmaceutical companies with extensive expertise in several Chemical Biology-related disciplines such as Drug Screening, Bio-analytical Chemistry, Receptor Biochemistry, DNA and Protein Chemistry. Dr Turcatti earned his Master in Chemical Engineering at the University of Geneva and his PhD in Chemistry and Biochemistry from the EPFL where he received the award for the best doctoral thesis of the year.
Selection of Label-free Cellular Imaging Applications for their Integration in the Screening Strategy
Video May 08, 2015
CryostaX® hepatocytes are created using a patented process that produces unique single-donor cell pellets. This format allows for distinct benefits to hepatocyte performance, efficiency in the lab, and test system design, precipitating the potential discontinuation of cryopreserved hepatocytes prepared from traditional methods. This webinar will discuss the technology, its optimal utilization and benefitsWATCH NOW